Zenas Biopharma Inc

CEO Leon Moulder’s fresh Zenas Biopharma share purchases reveal strong insider confidence ahead of Phase II data, suggesting potential upside for investors.

Insider buying signals optimism for Zenas Biopharma: Lu Hongbo adds 75k shares at $20, boosting confidence amid a volatile share price and rising social‑media buzz.

Fairmount Funds Management’s $3 million purchase of 150 k Zenas Biopharma shares at $20.00 shows a cautious yet bullish stance on the company’s clinical pipeline, offering long‑term investors a potentially strategic entry point amid market volatilit…

CEO insider buying at Zenas Biopharma signals confidence amid volatile pricing and a promising immunology pipeline, urging investors to consider holding or adding shares.

Insider buying surge at Zenas Biopharma shows modest confidence amid a 21 % weekly rally; incremental purchases hint at potential upside tied to upcoming clinical milestones.

Insider buying surge at Zenas Biopharma signals growing confidence in its immunology pipeline and potential upside, while highlighting the importance of clinical milestones and regulatory developments.

CEO Leon Moulder’s 100k‑share buying spree shows insider confidence in Zenas Biopharma’s immunology pipeline, hinting at a rebound amid volatile stock swings.